GREGORY JULIA P 4

Accession 0001562180-22-007079

CIK 0001935979other

View on SEC.gov Company Profile

Filed

Oct 4, 8:00 PM ET

Accepted

Oct 5, 5:39 PM ET

Size

31.6 KB

Accession

0001562180-22-007079

Insider Transaction Report

Form 4

Period: 2022-10-03

Biohaven Ltd.BHVN

GREGORY JULIA P

Director

Transactions

Other
Stock Options (Right to Buy)
2022-10-03+9,000→ 9,000 total
Exercise: $3.06Exp: 2029-05-20→ Common Shares (9,000 underlying)
Exercise/Conversion
Stock Options (Right to Buy)
2022-10-03−9,000→ 0 total
Exercise: $2.33Exp: 2030-04-29→ Common Shares (9,000 underlying)
Exercise/Conversion
Common Shares
2022-10-03$3.06/sh+9,000$27,540→ 28,117 total
Exercise/Conversion
Stock Options (Right to Buy)
2022-10-03−5,998→ 0 total
Exercise: $3.56Exp: 2031-05-05→ Common Shares (5,998 underlying)
Exercise/Conversion
Common Shares
2022-10-03$4.84/sh+4,119$19,936→ 4,119 total
Exercise/Conversion
Common Shares
2022-10-03$2.33/sh+9,000$20,970→ 19,117 total
Exercise/Conversion
Common Shares
2022-10-03$3.56/sh+5,998$21,353→ 10,117 total
Tax Payment
Common Shares
2022-10-03$7.50/sh−11,975$89,813→ 16,142 total
Other
Stock Options (Right to Buy)
2022-10-03+5,998→ 5,998 total
Exercise: $3.56Exp: 2031-05-05→ Common Shares (5,998 underlying)
Other
Stock Options (Right to Buy)
2022-10-03+4,119→ 4,119 total
Exercise: $4.84Exp: 2032-04-28→ Common Shares (4,119 underlying)
Other
Stock Options (Right to Buy)
2022-10-03+9,000→ 9,000 total
Exercise: $2.33Exp: 2030-04-29→ Common Shares (9,000 underlying)
Exercise/Conversion
Stock Options (Right to Buy)
2022-10-03−4,119→ 0 total
Exercise: $4.84Exp: 2032-04-28→ Common Shares (4,119 underlying)
Exercise/Conversion
Stock Options (Right to Buy)
2022-10-03−9,000→ 0 total
Exercise: $3.06Exp: 2029-05-20→ Common Shares (9,000 underlying)
Award
Stock Options (Right to buy)
2022-10-03+125,000→ 125,000 total
Exercise: $7.00Exp: 2032-10-04→ Common Shares (125,000 underlying)

Footnotes (3)

[F1]These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options.
[F2]Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement
[F3]The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Documents

1 file

4
primarydocument.xmlPrimary
PRIMARY DOCUMENT

Issuer

Biohaven Ltd.

CIK 0001935979

→

Entity typeother

Related Parties

filerCIK 0001226675

Filing Metadata

Form type: 4
Filed: Oct 4, 8:00 PM ET
Accepted: Oct 5, 5:39 PM ET
Size: 31.6 KB

View on SEC.gov